Additive impulsivity and emotion dysregulation in adolescents with comorbid bipolar and substance use disorder: a cross-sectional factorial study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impulsivity and Emotion Regulation Challenges in Adolescents with Co-occurring Bipolar Disorder and Substance Use Disorder: Findings from a Cross-Sectional Factorial Analysis

  • By

  • Fevzi T. Ocakoglu

  • Yiğit Özaydın

  • Naz Arslan

  • Birsen Şentürk Pilan

  • Tezan Bildik

  • Eyup S. Ercan

  • June 5, 2026

Share

  • 1

    Adolescents with comorbid bipolar disorder and substance use disorder exhibit higher impulsivity and emotion regulation difficulties than those with either disorder alone.

  • 2

    The study found significant interactions between bipolar disorder and substance use disorder affecting both impulsivity and emotion regulation in adolescents.

  • 3

    The BD+SUD group scored 38.90 points higher on emotion dysregulation and 26.72 points higher on impulsivity compared to the SUD-only group.

  • 4

    Impulsivity was identified as the strongest predictor of substance use severity among adolescents with substance use disorder.

  • 5

    Findings suggest the need for integrated interventions targeting impulsivity and emotion regulation in adolescents with dual diagnoses.

Original Source(s)

Additive impulsivity and emotion dysregulation in adolescents with comorbid bipolar and substance use disorder: a cross-sectional factorial study

  • by Fevzi T. Ocakoglu, Yiğit Özaydın, Naz Arslan, Birsen Şentürk Pilan, Tezan Bildik, Eyup S. Ercan

  • June 5, 2026

Related Content

The impact of problematic social media use on adolescent subjective well-being: insights from machine learning

Thyroid-stimulating hormone, fasting blood glucose and suicidal ideation in Chinese adolescents with major depressive disorder: a cross-sectional study

Can SGLT2 Inhibitors Affect Dementia?

A target trial emulation using Veterans Affairs electronic health records examined neuropsychiatric outcomes associated with SGLT2 inhibitor use.